Progyny Inc (NASDAQ:PGNY) Major Shareholder Sells $4,099,332.00 in Stock

Progyny Inc (NASDAQ:PGNY) major shareholder Group Holdings (Sbs) Advis Tpg sold 150,600 shares of the company’s stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $27.22, for a total value of $4,099,332.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Holdings (Sbs) Advis Tpg also recently made the following trade(s):

  • On Tuesday, September 22nd, Group Holdings (Sbs) Advis Tpg sold 113,498 shares of Progyny stock. The shares were sold at an average price of $25.70, for a total value of $2,916,898.60.
  • On Friday, September 18th, Group Holdings (Sbs) Advis Tpg sold 168,514 shares of Progyny stock. The stock was sold at an average price of $26.85, for a total value of $4,524,600.90.
  • On Monday, September 14th, Group Holdings (Sbs) Advis Tpg sold 10,287 shares of Progyny stock. The stock was sold at an average price of $26.90, for a total value of $276,720.30.
  • On Thursday, September 10th, Group Holdings (Sbs) Advis Tpg sold 66,145 shares of Progyny stock. The stock was sold at an average price of $27.37, for a total value of $1,810,388.65.
  • On Friday, September 4th, Group Holdings (Sbs) Advis Tpg sold 57,979 shares of Progyny stock. The stock was sold at an average price of $26.75, for a total value of $1,550,938.25.
  • On Wednesday, September 2nd, Group Holdings (Sbs) Advis Tpg sold 48,151 shares of Progyny stock. The stock was sold at an average price of $28.91, for a total value of $1,392,045.41.
  • On Wednesday, August 26th, Group Holdings (Sbs) Advis Tpg sold 53,213 shares of Progyny stock. The stock was sold at an average price of $28.29, for a total value of $1,505,395.77.
  • On Monday, August 24th, Group Holdings (Sbs) Advis Tpg sold 13,994 shares of Progyny stock. The stock was sold at an average price of $28.57, for a total value of $399,808.58.
  • On Friday, August 21st, Group Holdings (Sbs) Advis Tpg sold 91,006 shares of Progyny stock. The stock was sold at an average price of $30.49, for a total value of $2,774,772.94.
  • On Thursday, August 13th, Group Holdings (Sbs) Advis Tpg sold 12,466 shares of Progyny stock. The stock was sold at an average price of $29.80, for a total value of $371,486.80.

Progyny stock opened at $28.62 on Monday. Progyny Inc has a one year low of $13.29 and a one year high of $36.50. The stock has a market capitalization of $2.46 billion and a PE ratio of -24.89. The business’s fifty day moving average is $28.07 and its 200 day moving average is $24.67.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. Progyny had a positive return on equity of 10.04% and a negative net margin of 3.81%. The company had revenue of $64.61 million for the quarter, compared to analysts’ expectations of $46.86 million. As a group, research analysts anticipate that Progyny Inc will post 0.12 earnings per share for the current fiscal year.

A number of equities analysts have issued reports on the company. ValuEngine downgraded Progyny from a “buy” rating to a “hold” rating in a report on Wednesday, September 9th. JPMorgan Chase & Co. raised their price target on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, August 24th. Bank of America raised their price target on Progyny from $26.00 to $28.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Piper Sandler raised their price target on Progyny from $32.00 to $33.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Guggenheim initiated coverage on Progyny in a report on Tuesday, June 2nd. They set a “buy” rating and a $30.00 price target for the company. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $32.44.

Several institutional investors have recently added to or reduced their stakes in the stock. Macquarie Group Ltd. boosted its position in shares of Progyny by 21.3% during the second quarter. Macquarie Group Ltd. now owns 3,512,773 shares of the company’s stock valued at $90,665,000 after buying an additional 617,246 shares during the last quarter. Vanguard Group Inc. boosted its position in Progyny by 132.7% in the second quarter. Vanguard Group Inc. now owns 2,520,042 shares of the company’s stock worth $65,041,000 after purchasing an additional 1,437,114 shares during the last quarter. Fred Alger Management LLC boosted its position in Progyny by 261.8% in the first quarter. Fred Alger Management LLC now owns 2,009,533 shares of the company’s stock worth $42,582,000 after purchasing an additional 1,454,157 shares during the last quarter. Clearbridge Investments LLC boosted its position in Progyny by 12.5% in the first quarter. Clearbridge Investments LLC now owns 1,619,494 shares of the company’s stock worth $34,317,000 after purchasing an additional 180,432 shares during the last quarter. Finally, FMR LLC boosted its position in Progyny by 163.3% in the second quarter. FMR LLC now owns 1,093,386 shares of the company’s stock worth $28,220,000 after purchasing an additional 678,054 shares during the last quarter. 54.09% of the stock is currently owned by institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Read More: What is a Tariff?

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.